CIRB Studies

Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.

To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.

Displaying 11 - 20 of 819
Study Number Lead Group Study Title CIRB Study Status
WF-30917CD NCORP-Wake Forest University A Stepped-Care Telehealth Approach to Treat Distress in Rural Cancer Survivors Cancer Prevention and Control CIRB Available to Open
S1600 SWOG A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes Cancer Prevention and Control CIRB Available to Open
PBTC-055 PBTC Phase I/II trial of Dabrafenib, Trametinib, and Hydroxychloroquine (HCQ) for BRAF V600E-mutant or Trametinib and HCQ for BRAF fusion/duplication positive or NF1-associated recurrent or progressive gliomas in children and young adults Pediatric CIRB Available to Open
9853 ETCTN A Phase 1 Study of AZD1775 in Combination with Belinostat in Relapsed and Refractory Myeloid Malignancies and Selected Untreated Patients with Acute Myeloid Leukemia Adult CIRB - Early Phase Emphasis Available to Open
NRG-BR001 RTOG A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases Adult CIRB - Early Phase Emphasis Available to Open
E1910 ECOG A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults Adult CIRB - Late Phase Emphasis Available to Open
ACNS1123 COG Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT): A Groupwide Phase II Study Pediatric CIRB Available to Open
ANBL0532 COG Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma: A Groupwide Phase III Study Pediatric CIRB Available to Open
ADVL1414 COG A Phase 1 Study of Selinexor (KPT-330; IND #125052); A Selective XPO1 Inhibitor; In Recurrent and Refractory Pediatric Solid Tumors; Including CNS Tumors Pediatric CIRB Available to Open
A041703 Alliance Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults with Relapsed or Refractory Disease Adult CIRB - Late Phase Emphasis Available to Open
Displaying 11 - 20 of 819